Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
KSPI -21.66%, BMRN -16.74%, RIVN -13.26%, FDX -11.08%, BNTX -9.01%, AJG -7.17%, CHWY -6.97%, NVO -6.93%, MUSA -6.90% ...
Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today
The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.
Novo Nordisk Sinks on Obesity Drug Study's Disappointing Results
Key Takeaways Novo Nordisk's U.S.-listed shares lost ground Friday after a Phase 2a trial of the pharmaceutical firm’s latest ...
J.P. Morgan Sticks to Their Buy Rating for Novo Nordisk (0QIU)
J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...
WSAY2d
Novo Nordisk shares drop nearly 5% on disappointing obesity pill data
By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -Novo Nordisk's shares fell nearly 5% on Friday after ...
Novo Nordisk Slips On Phase 2a Clinical Trial Result With Monlunabant
Friday, shares of Novo Nordisk A/S (NVO) are sliding following the announcement of safety results of phase 2a clinical trial of ...
High-Flying Novo Nordisk Dips On Disappointing Data for Weight-Loss Pill
Novo Nordisk’s American depositary receipts tumbled almost 6% Friday after the drugmaker reported mixed results from a study of an experimental weight-loss pill. The pill, monlunabant, helped people ...
sn2d
Novo-aktien dykker markant efter skuffelse fra slankepille
Novo Nordisk-aktien har fredag oplevet et fald på 5,4 procent. Det står klart fredag eftermiddag efter børslukning. Aktien ...
berlingske.dk2d
Dansk forsker modtager den »amerikanske Nobelpris«
Torsdag blev vinderne af Lasker-prisen offentliggjort i New York. Prisen, der er bedre kendt som det amerikanske svar på ...
Ekstra Bladet2d
Ny fedmedata skuffer: Novo-aktien sendt i bund
Nye fedmedata for midlet Monlunabant i tabletform er nemlig blevet offentliggjort, og det er ikke så godt som håbet - ...
Euroinvestor2d
Nordnet: Derfor falder Novo Nordisk-aktien nu
Novo Nordisk -aktien falder tungt fredag eftermiddag, og det er der en helt særlig grund til. Det mener Per Hansen, der er ...
Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed
Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1]. The trial investigated ...